Polycystic Ovary Syndrome (PCOS). Polycystic Ovary Syndrome (PCOS)
Conditions
Interventions
Intervention 1: Intervention group: Women with polycystic ovary syndrome receiving one 100 mg coenzyme Q10 supplement daily for 8 weeks. Intervention 2: Control group: Women with polycystic ovary synd
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Consent to participate and cooperate in the study Individuals aged 18–45 years Individuals with a body mass index (BMI) of 18.5–35 Maximum of 6 months since diagnosis of polycystic ovary syndrome (PCOS)
Exclusion criteria
Exclusion criteria: Presence of underlying diseases (uncontrolled diabetes, stage 3 or 4 heart failure, thyroid disorders, renal disorders, and cancer) Use of other antioxidant supplements, including vitamin E, vitamin C, selenium, and omega-3, in the past 3 months Prior use of coenzyme Q10 supplements before study enrollment Use of anti-inflammatory drugs and corticosteroids Smoking, alcohol, or hookah consumption Menopause Pregnancy and breastfeeding Severe reaction to supplements or placebos Development of other chronic diseases during the intervention Death during the study process Lack of interest in continuing participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight: The mean weight change (kg) measured using a calibrated digital scale. Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take coenzyme Q10 supplement. Method of measurement: Measured using a calibrated digital scale.;Height: Height (cm) measured using a stadiometer in a standing position. Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take coenzyme Q10 supplement. Method of measurement: Measured using a stadiometer in a standing position.;BMI: Body mass index calculated as weight (kg) divided by the square of height (m). Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take coenzyme Q10 supplement. Method of measurement: Body mass index based on the formula of weight (kilograms) divided by the square of height (meters).;Waist Circumference: Waist circumference (cm) measured using a tape measure at the level of the umbilicus. Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take coenzyme Q10 supplement. Method of measurement: Measured (cm) using a measuring tape.;IL-6: The mean level of interleukin-6 (pg/mL) measured using the enzyme-linked immunosorbent assay (ELISA). Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take coenzyme Q10 supplement. Method of measurement: Measured using the enzyme-linked immunosorbent assay (ELISA)(serum level).;Hs-CRP: High-sensitivity C-reactive protein (mg/L) measured using the ELISA method. Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take coenzyme Q10 supplement. Method of measurement: Measured using the ELISA method (serum level).;SOD: Superoxide dismutase activity (U/mg protein) measured using the ELISA method. Timepoint: Variable measurement is done at the beginning of the study and 8 weeks after starting to take co | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSima Jafari Rad
Ahvaz University of Medical Sciences
Outcome results
None listed